Swanepoel T, Moller M, Harvey B
Psychopharmacology (Berl). 2017; 235(1):351-368.
PMID: 29116368
DOI: 10.1007/s00213-017-4776-5.
Vieira-Brock P, McFadden L, Nielsen S, Ellis J, Walters E, Stout K
J Pharmacol Exp Ther. 2015; 355(3):463-72.
PMID: 26391161
PMC: 4658490.
DOI: 10.1124/jpet.114.221945.
Kaushal N, Robson M, Rosen A, McCurdy C, Matsumoto R
Eur J Pharmacol. 2014; 724:193-203.
PMID: 24380829
PMC: 3993961.
DOI: 10.1016/j.ejphar.2013.12.039.
German C, Fleckenstein A, Hanson G
Life Sci. 2013; 97(1):2-8.
PMID: 23911668
PMC: 3909723.
DOI: 10.1016/j.lfs.2013.07.023.
McFadden L, Hanson G, Fleckenstein A
Synapse. 2013; 67(12):875-81.
PMID: 23893609
PMC: 3962656.
DOI: 10.1002/syn.21696.
N-Acetyl Cysteine Protects against Methamphetamine-Induced Dopaminergic Neurodegeneration via Modulation of Redox Status and Autophagy in Dopaminergic Cells.
Shivalingappa P, Jin H, Anantharam V, Kanthasamy A, Kanthasamy A
Parkinsons Dis. 2012; 2012:424285.
PMID: 23056996
PMC: 3465903.
DOI: 10.1155/2012/424285.
Pharmacological evaluation of SN79, a sigma (σ) receptor ligand, against methamphetamine-induced neurotoxicity in vivo.
Kaushal N, Seminerio M, Robson M, McCurdy C, Matsumoto R
Eur Neuropsychopharmacol. 2012; 23(8):960-71.
PMID: 22921523
PMC: 3748261.
DOI: 10.1016/j.euroneuro.2012.08.005.
Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations.
McFadden L, Hunt M, Vieira-Brock P, Muehle J, Nielsen S, Allen S
Drug Alcohol Depend. 2012; 126(1-2):87-94.
PMID: 22647900
PMC: 3546538.
DOI: 10.1016/j.drugalcdep.2012.04.020.
Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.
McFadden L, Hoonakker A, Vieira-Brock P, Stout K, Sawada N, Ellis J
Synapse. 2010; 65(8):771-7.
PMID: 21190217
PMC: 3908924.
DOI: 10.1002/syn.20902.
The role of endogenous serotonin in methamphetamine-induced neurotoxicity to dopamine nerve endings of the striatum.
Thomas D, Angoa Perez M, Francescutti-Verbeem D, Shah M, Kuhn D
J Neurochem. 2010; 115(3):595-605.
PMID: 20722968
PMC: 2974310.
DOI: 10.1111/j.1471-4159.2010.06950.x.
Amphetamine toxicities: classical and emerging mechanisms.
Yamamoto B, Moszczynska A, Gudelsky G
Ann N Y Acad Sci. 2010; 1187:101-21.
PMID: 20201848
PMC: 3955986.
DOI: 10.1111/j.1749-6632.2009.05141.x.
Determining the subjective and physiological effects of BZP on human females.
Lin J, Bangs N, Lee H, Kydd R, Russell B
Psychopharmacology (Berl). 2009; 207(3):439-46.
PMID: 19777213
DOI: 10.1007/s00213-009-1669-2.
Methamphetamine toxicity and messengers of death.
Krasnova I, Cadet J
Brain Res Rev. 2009; 60(2):379-407.
PMID: 19328213
PMC: 2731235.
DOI: 10.1016/j.brainresrev.2009.03.002.
Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications.
Fleckenstein A, Volz T, Hanson G
Neuropharmacology. 2008; 56 Suppl 1:133-8.
PMID: 18662707
PMC: 2634813.
DOI: 10.1016/j.neuropharm.2008.07.002.
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence.
Shoptaw S, Heinzerling K, Rotheram-Fuller E, Steward T, Wang J, Swanson A
Drug Alcohol Depend. 2008; 96(3):222-32.
PMID: 18468815
PMC: 3652530.
DOI: 10.1016/j.drugalcdep.2008.03.010.
Mechanisms of methamphetamine-induced dopaminergic neurotoxicity.
Riddle E, Fleckenstein A, Hanson G
AAPS J. 2006; 8(2):E413-8.
PMID: 16808044
PMC: 3231576.
DOI: 10.1007/BF02854914.
Causes and consequences of methamphetamine and MDMA toxicity.
Quinton M, Yamamoto B
AAPS J. 2006; 8(2):E337-47.
PMID: 16796384
PMC: 3231568.
DOI: 10.1007/BF02854904.
Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice.
Forsberg M, Juvonen R, Helisalmi P, Leppanen J, Gogos J, Karayiorgou M
Naunyn Schmiedebergs Arch Pharmacol. 2004; 370(4):279-89.
PMID: 15378229
DOI: 10.1007/s00210-004-0967-9.
Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism.
Baucum 2nd A, Rau K, Riddle E, Hanson G, Fleckenstein A
J Neurosci. 2004; 24(13):3436-43.
PMID: 15056723
PMC: 6730025.
DOI: 10.1523/JNEUROSCI.0387-04.2004.
Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.
Fumagalli F, Gainetdinov R, Wang Y, Valenzano K, Miller G, Caron M
J Neurosci. 1999; 19(7):2424-31.
PMID: 10087057
PMC: 6786062.